Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034860134> ?p ?o ?g. }
- W3034860134 abstract "Background: Dofetilide is one of the only anti-arrhythmic agents approved for atrial fibrillation (AF) in patients with reduced left ventricular ejection fraction (LVEF). However, postapproval data and safety outcomes are limited. In this study, we assessed the incidence and predictors of LVEF improvement, safety, and outcomes in patients with AF with LVEF ≤35% without prior implantable cardioverter defibrillator, cardiac resynchronization therapy, or AF ablation. Methods: An analysis of 168 consecutive patients from 2007 to 2016 was performed. Incidences of adverse events, drug continuation, implantable cardioverter defibrillator and cardiac resynchronization therapy implantation, LVEF improvement (>35%) and recovery (≥50%), AF recurrence, and AF ablation were determined. Multivariable regression analysis to identify predictors of LVEF improvement/recovery was performed. Results: The mean age was 64±12 years. Dofetilide was discontinued before hospital discharge in 46 (27%) because of QT prolongation (14%), torsades de pointe or polymorphic ventricular tachycardia/fibrillation (6% [sustained 3%, nonsustained 3%]), ineffectiveness (5%), or other causes (3%). At 1 year, 43% remained on dofetilide. Freedom from AF was 42% at 1 year, and 40% underwent future AF ablation. LVEF recovered (≥50%) in 45% and improved to >35% in 73%. Predictors of LVEF improvement included presence of AF during echocardiogram (odds ratio, 4.22 [95% CI, 1.71–10.4], P =0.002), coronary artery disease (odds ratio, 0.35 [95% CI, 0.16–0.79], P =0.01), left atrial diameter (odds ratio, 0.52 per 1 cm increase [95% CI, 0.30–0.90], P =0.01), and LVEF (odds ratio, per 1% increase, 1.09 [95% CI, 1.02–1.16], P =0.006). The C statistic was 0.78. Conclusions: In patients with LVEF ≤35%, who are potential implantable cardioverter defibrillator candidates, treated with dofetilide as an initial anti-arrhythmic strategy for AF, drug discontinuation rates were high, and many underwent future AF ablation. However, most patients had improvement in LVEF, obviating the need for primary prevention implantable cardioverter defibrillator." @default.
- W3034860134 created "2020-06-19" @default.
- W3034860134 creator A5000769004 @default.
- W3034860134 creator A5003438591 @default.
- W3034860134 creator A5007994748 @default.
- W3034860134 creator A5009865705 @default.
- W3034860134 creator A5021078245 @default.
- W3034860134 creator A5022913157 @default.
- W3034860134 creator A5031053016 @default.
- W3034860134 creator A5033048744 @default.
- W3034860134 creator A5035774466 @default.
- W3034860134 creator A5036210507 @default.
- W3034860134 creator A5046071151 @default.
- W3034860134 creator A5051621921 @default.
- W3034860134 creator A5053021028 @default.
- W3034860134 creator A5059339867 @default.
- W3034860134 creator A5074710268 @default.
- W3034860134 creator A5076218745 @default.
- W3034860134 creator A5076919385 @default.
- W3034860134 creator A5084723768 @default.
- W3034860134 creator A5086285030 @default.
- W3034860134 date "2020-07-01" @default.
- W3034860134 modified "2023-10-10" @default.
- W3034860134 title "Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator" @default.
- W3034860134 cites W1880644021 @default.
- W3034860134 cites W1965658674 @default.
- W3034860134 cites W2067232731 @default.
- W3034860134 cites W2101099004 @default.
- W3034860134 cites W2101986159 @default.
- W3034860134 cites W2107020336 @default.
- W3034860134 cites W2108928593 @default.
- W3034860134 cites W2114270660 @default.
- W3034860134 cites W2271687503 @default.
- W3034860134 cites W2314139393 @default.
- W3034860134 cites W2348720246 @default.
- W3034860134 cites W2504295490 @default.
- W3034860134 cites W2514172728 @default.
- W3034860134 cites W2747726107 @default.
- W3034860134 cites W2786781710 @default.
- W3034860134 doi "https://doi.org/10.1161/circep.119.008168" @default.
- W3034860134 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32538135" @default.
- W3034860134 hasPublicationYear "2020" @default.
- W3034860134 type Work @default.
- W3034860134 sameAs 3034860134 @default.
- W3034860134 citedByCount "3" @default.
- W3034860134 countsByYear W30348601342020 @default.
- W3034860134 countsByYear W30348601342021 @default.
- W3034860134 countsByYear W30348601342022 @default.
- W3034860134 crossrefType "journal-article" @default.
- W3034860134 hasAuthorship W3034860134A5000769004 @default.
- W3034860134 hasAuthorship W3034860134A5003438591 @default.
- W3034860134 hasAuthorship W3034860134A5007994748 @default.
- W3034860134 hasAuthorship W3034860134A5009865705 @default.
- W3034860134 hasAuthorship W3034860134A5021078245 @default.
- W3034860134 hasAuthorship W3034860134A5022913157 @default.
- W3034860134 hasAuthorship W3034860134A5031053016 @default.
- W3034860134 hasAuthorship W3034860134A5033048744 @default.
- W3034860134 hasAuthorship W3034860134A5035774466 @default.
- W3034860134 hasAuthorship W3034860134A5036210507 @default.
- W3034860134 hasAuthorship W3034860134A5046071151 @default.
- W3034860134 hasAuthorship W3034860134A5051621921 @default.
- W3034860134 hasAuthorship W3034860134A5053021028 @default.
- W3034860134 hasAuthorship W3034860134A5059339867 @default.
- W3034860134 hasAuthorship W3034860134A5074710268 @default.
- W3034860134 hasAuthorship W3034860134A5076218745 @default.
- W3034860134 hasAuthorship W3034860134A5076919385 @default.
- W3034860134 hasAuthorship W3034860134A5084723768 @default.
- W3034860134 hasAuthorship W3034860134A5086285030 @default.
- W3034860134 hasBestOaLocation W30348601341 @default.
- W3034860134 hasConcept C126322002 @default.
- W3034860134 hasConcept C156957248 @default.
- W3034860134 hasConcept C164705383 @default.
- W3034860134 hasConcept C2776034619 @default.
- W3034860134 hasConcept C2776131983 @default.
- W3034860134 hasConcept C2776331378 @default.
- W3034860134 hasConcept C2777093960 @default.
- W3034860134 hasConcept C2777796741 @default.
- W3034860134 hasConcept C2778198053 @default.
- W3034860134 hasConcept C2779161974 @default.
- W3034860134 hasConcept C71924100 @default.
- W3034860134 hasConcept C78085059 @default.
- W3034860134 hasConceptScore W3034860134C126322002 @default.
- W3034860134 hasConceptScore W3034860134C156957248 @default.
- W3034860134 hasConceptScore W3034860134C164705383 @default.
- W3034860134 hasConceptScore W3034860134C2776034619 @default.
- W3034860134 hasConceptScore W3034860134C2776131983 @default.
- W3034860134 hasConceptScore W3034860134C2776331378 @default.
- W3034860134 hasConceptScore W3034860134C2777093960 @default.
- W3034860134 hasConceptScore W3034860134C2777796741 @default.
- W3034860134 hasConceptScore W3034860134C2778198053 @default.
- W3034860134 hasConceptScore W3034860134C2779161974 @default.
- W3034860134 hasConceptScore W3034860134C71924100 @default.
- W3034860134 hasConceptScore W3034860134C78085059 @default.
- W3034860134 hasIssue "7" @default.
- W3034860134 hasLocation W30348601341 @default.
- W3034860134 hasLocation W30348601342 @default.
- W3034860134 hasOpenAccess W3034860134 @default.
- W3034860134 hasPrimaryLocation W30348601341 @default.
- W3034860134 hasRelatedWork W1551189864 @default.
- W3034860134 hasRelatedWork W187959415 @default.